Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα has prognostic significance only in ccRCC tumors.
|
31258735 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Whereas, after the addition of circPVT1, this effect no longer worked, suggesting that circPVT1 may affect the malignancy of the tumor by affecting miRNA and regulating the levels of Paxs and PPARs.
|
31636510 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
shRNA-mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth.
|
30565681 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway.
|
31539552 |
2019 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our analysis reveals underappreciated levels of diversity and conservation in PPAR genes that could lay the groundwork for therapeutic strategies targeting tumor metabolism, immunity, and hypoxia.
|
31215667 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upstream regulator analysis highlighted transcriptional regulation by peroxisome proliferator-activated receptor alpha (PPARα) in the liver and kidney and by tumor protein/suppressor p53 (TP53) in the thymus, spleen, and liver.
|
30186752 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PPARα expression was unrelated to gonadotroph differentiation in NFPA, but positively correlated with tumour volume in PRL-PA.
|
30021235 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We also found higher PPARα expression in the tumor area than adjacent areas and subsequently compared PPARα expression in four different hepatic cancer cell lines.
|
29134746 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Multivariate Cox analyses indicated that tumor size (<i>P</i>=0.001), TNM stage (<i>P</i><0.001), vascular invasion (<i>P</i><0.001), and PPARα expression in the cytoplasm (<i>P</i><0.001) were found to be independent prognostic variables for overall survival.
|
29983595 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PFCAs, especially those having longer carbon chain lengths (≥C6), are associated with developmental and hormonal effects, immunotoxicity, and promote tumor growth in rodents through their role as PPARα agonists.
|
27876672 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
5) Peroxisome proliferators do not promote tumour formation in human liver as opposed to mouse liver because of structural and functional differences between human and mouse PPARα.
|
28077274 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, genetic knockouts of PPARα have been shown to be protected against tumor growth in a variety of syngeneic tumors models.
|
28483457 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα was previously indicated by us as a potential therapeutic target for this neoplasm, due to the malignancy grade dependency of its expression, being particularly abundant in GB.
|
27736000 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We further confirmed that depletion of PPARα resulted in low CPT1C expression and then inhibited proliferation and induced senescence of MDA-MB-231 and PANC-1 tumor cell lines in a CPT1C-dependent manner, while forced PPARα overexpression promoted cell proliferation and reversed cellular senescence.
|
28334197 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of peroxisome proliferator-activated receptor alpha (PPARα) has been reported to disrupt tumour metabolism and to promote anticancer activity through interfering with the Warburg effect.
|
28453233 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-α receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors.
|
25092647 |
2014 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα is a nuclear receptor protein that functions as a transcription factor for genes including those encoding enzymes involved in energy metabolism; while PPARα has been reported to regulate tumor growth in several cancers, it has not been evaluated in RCC.
|
23951092 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although PPARα expression was also increased in the n-3 PUFA-enriched diet group under docetaxel treatment, it is only the expression of PPARβ mRNA that correlated with the regression of mammary tumors: those that most regressed displayed the lowest PPARβ mRNA expression.
|
23906790 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, this study demonstrates that loss of expression of GMPR2 and PPARα is associated with BP at the protein level; indicating that they may play a role in carcinogenesis of this molecularly complex and clinically important subtype.
|
23208589 |
2013 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of peroxisome proliferator-activated receptor α (PPARα) has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain to be characterized.
|
22932900 |
2012 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Administration of a novel NOX-specific inhibitor reduced angiogenesis and tumor growth in vivo in a PPARα dependent manner.
|
21326871 |
2011 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings may also reveal the possibility of using the level of endogenous PPARγ ligands and the activities of PPARγ or PPARα as tumor markers for lung cancer.
|
20081051 |
2010 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Optimal cutoff values were determined for each relative expression ratio (RER) (RER = PPAR expression of tumor/PPAR expression of normal mucosa) of PPAR, and patients were divided into two groups as follows (PPAR staging): patients with elevated RERs of PPAR gamma (> 2.0) or PPAR delta (> 1.0) were termed Group H, and patients showing none of these elevated RERs of PPARs were termed Group L. Prognostic significance was analyzed by univariate and Kaplan-Meier analyses.
|
19283612 |
2009 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARalpha activation causes inhibition of migration of melanoma cells and anchorage-independent growth, whereas primary tumor growth remains unaltered.
|
18092840 |
2008 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, both genetic abrogation of PPARalpha as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways.
|
18199835 |
2008 |